US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters
Quartz FDA declined to approve Summit Therapeutics' lung cancer drug
The agency said ivonescimab lacks a statistically significant overall survival benefit; Summit said it will continue development
Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: G/O Media


















